Colorectal cancer (CRC) remains a formidable global health challenge, with over 1.9 million new cases annually and a pressing need for therapies that address tumor heterogeneity, metastasis, and resistance. At Alfa Cytology, we specialize in preclinical therapeutic development services that bridge the gap between innovative discoveries and clinical success. Our scientifically rigorous, translationally validated solutions empower biopharmaceutical companies and research institutions to accelerate CRC drug development with confidence.
Despite advances in targeted and immunotherapies, critical gaps persist:
Resistance: Over 50% of CRC patients develop resistance to EGFR/BRAF inhibitors.
Metastasis: Liver/lung metastases drive 90% of CRC-related deaths.
Tumor Microenvironment (TME) Complexity: Stromal and immune cell interactions limit therapeutic efficacy.
At Alfa Cytology, we tackle these challenges head-on with models, technologies, and expertise designed to de-risk your pipeline.
Targeted Therapy Development
Focus Areas: KRAS/BRAF mutations, HER2 amplification, Wnt/β-catenin signaling.
In Vitro/In Vivo Models:
PDX Models: Maintain patient-specific mutations (e.g., KRAS G12C, BRAF V600E) for efficacy testing.
CRISPR-Engineered Lines: Study oncogene addiction and synthetic lethality.
Resistance Mechanisms: Track clonal evolution via longitudinal ctDNA analysis.
Immunotherapy Development
Focus Areas: Checkpoint inhibitors, CAR-T, cancer vaccines.
Humanized Models:
huCD34+ Mice: Evaluate PD-1/PD-L1 inhibitors in immune-competent settings.
MSS-CRC Models: Test T-cell engagers or cytokine therapies in “cold” tumors.
Biomarker Discovery: Identify responders via spatial transcriptomics or multiplex IHC.
ADC & Biologic Therapeutics
Focus Areas: HER2/TROP2 ADCs, bispecific antibodies.
Payload Optimization: Quantify bystander effects in heterogeneous tumors.
In Vivo Biodistribution: Track ADC tumor penetration using near-infrared imaging.
Safety Profiling: Assess off-target toxicity in GLP-compliant studies.
At Alfa Cytology, we streamline colorectal cancer (CRC) therapeutic development through a collaborative, milestone-driven workflow. Our process integrates cutting-edge science, regulatory foresight, and client-centric flexibility to accelerate your drug’s path to the clinic.
Target Identification
Lead Compound Screening
In Vivo Efficacy Testing
Whether you’re advancing a small molecule, biologic, or cutting-edge modality, we deliver:
End-to-End Expertise: Target validation → IND-enabling studies.
Tailored Solutions: Subtype-specific models (e.g., CMS4, RAS-mutant).
IP Protection: Secure workflows with full data ownership.
Schedule a Consultation to align your program with clinical and commercial goals. If you are interested in our service program, feel free to contact us.
For research use only.
